Skip to main content
. 2020 May 14;9(1):1760685. doi: 10.1080/2162402X.2020.1760685

Figure 4.

Figure 4.

Effect of AXT201 treatment on lymphocyte populations in 4T1 tumors. (a-c) Percentage of CD4+ T cells (a), CD8+ T cells (b), and Tregs (c) out of all live cells from isolated whole 4T1 tumor samples. N ≥ 10, *p < .05, Mann-Whitney test. (d-k) Percentage of subpopulations out of total (d-j) or out of effector (k) CD8+ T-cells from whole CD8+ T-cells isolated from 4T1 tumors by negative selection and stimulated overnight. (d-f) Percentage of CD8+ T cells expressing the secreted factors IFNγ (d), Granzyme B (e), or TNFα (f). (g) Owing to high variability in baseline levels between experimental sets, the percentage of CD8+ T cells expressing IL-2 from each tumor in an experimental set was normalized to average for all controls of that same set. Pre-normalized data can be found in Figure S4A. N ≥ 9, *p < .05, Student’s t-test. (h-k) Percentage of CD8+ T cells (h-l) or CD8+ effector T cells (m) expressing surface markers for (h) effector cells, (i) naïve T cells, (j) memory T cells, (k) the exhausted phenotype, (l) CTLA4 expression, or (m) PD-1 expression without Tim3 (activated). N ≥ 4, *p < .05, Mann-Whitney test.